STOCK TITAN
  1. Home
  2. News
  3. FUSN

Fusion Pharmaceuticals Inc - FUSN STOCK NEWS

Welcome to our dedicated news page for Fusion Pharmaceuticals (Ticker: FUSN), a resource for investors and traders seeking the latest updates and insights on Fusion Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fusion Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fusion Pharmaceuticals's position in the market.

News
BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) and BWXT Medical Ltd. have entered an agreement for the supply of generators to produce actinium-225, a medical isotope used in cancer treatment clinical trials. The agreement allows Fusion to access high-specific activity generator technology to produce actinium-225 at its GMP manufacturing facility, supporting the company's advancing pipeline of targeted alpha therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
News
Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) and BWXT Medical Ltd. have entered into a new agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials. This collaboration enables Fusion to produce high purity actinium-225 at the Company's GMP manufacturing facility, further solidifying BWXT Medical's position as a global leader in medical isotope supply. Actinium-225 is an alpha-emitting isotope used in Fusion's targeted alpha therapies (TATs) to kill cancer cells while minimizing the impact to healthy tissues. The agreement allows Fusion to have onsite production of actinium-225, providing superior flexibility in manufacturing schedules and increased capacity to support the clinical pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
News
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced the granting of stock options to two employees outside the 2020 Stock Option and Incentive Plan, as an inducement for joining the company. The options have an exercise price of $4.31 per share, equal to the closing price on November 6, 2023, and vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none
News
Fusion Pharmaceuticals to Present at Upcoming Investor Conferences
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announces participation in two investor conferences to present next-generation radiopharmaceuticals as precision medicines. CEO John Valliant to speak at Jefferies London Healthcare Conference on Nov 16, and CSO Christopher Leamon at Piper Sandler 35th Annual Healthcare Conference on Nov 29. Webcasts available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
conferences
-
News
Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced financial results for Q3 2023 and provided updates on clinical and corporate developments. The company is focused on developing next-generation radiopharmaceuticals for cancer treatment, with several programs in the pipeline. They are on track to report preliminary data for FPI-2265 in Q1 2024 and data from Cohort 2 of the FPI-1434 Phase 1 study around year-end 2023. Additionally, their state-of-the-art radiopharmaceutical manufacturing facility is set to begin producing clinical doses in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
earnings
-
News
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
Rhea-AI Summary
Fusion Pharmaceuticals announces the appointment of Jeremy Bender, Teresa Bitetti, and David Meek to its Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
management
News
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
Rhea-AI Summary
Fusion Pharmaceuticals presents preclinical data on FPI-2068 at cancer conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
clinical trial
-
News
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fusion Pharmaceuticals grants stock options to two employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.62%
Tags
none
-
News
Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences
Rhea-AI Summary
Fusion Pharmaceuticals Inc. will participate in two upcoming investor conferences: the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, and the Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023. The presentations will be given by Chief Financial Officer John Crowley and Chief Executive Officer John Valliant, Ph.D., respectively. Webcasts of each event will be available on the company's website, and a replay will be archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.61%
Tags
conferences
News
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
none
Stock FUSN logo
Fusion Pharmaceuticals Inc

NYSE:FUSN

FUSN Rankings

#2350 Ranked by Market Cap
#282 Ranked by Stock Gains
N/A Ranked by Dividends

FUSN Stock Data

1.81B
63.30M
4.41%
79.16%
6.14%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Canada
Hamilton

About FUSN

fusion pharmaceuticals (www.fusionpharma.com) is a new pharmaceutical company located in hamilton, ontario, canada, that is focused on becoming the leader in the targeted alpha therapy field. fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. in addition to its lead program, fpx-01, fusion is building a pipeline of products through a protein discovery platform, that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. fusion’s technology development team also has proprietary methods for introducing alpha emitters into targeting molecules.